Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Cytokinetics Inc shares valued at $65,820 were sold by Malik Fady Ibraham on Jun 17 ’25. At $32.91 per share, Malik Fady Ibraham sold 2,000 shares. The insider’s holdings dropped to 140,610 shares worth approximately $4.66 million following the completion of this transaction.
Also, Blum Robert I sold 5,000 shares, netting a total of over 169,000 in proceeds. Following the sale of shares at $33.80 each, the insider now holds 403,108 shares.
Before that, ROBERT BLUM had added 35,000 shares to its account. In a trade valued at $1,203,300, the Director bought Cytokinetics Inc shares for $34.38 each.
As published in their initiating research note from Barclays on April 24, 2025, Cytokinetics Inc [CYTK] has been an Overweight and the price target has been revised to $55. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in early February. As of January 22, 2025, Stifel has initiated its “Buy” rating for CYTK. Earlier on November 08, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CYTK stock.
Analyzing CYTK Stock Performance
On last trading session,, Cytokinetics Inc [NASDAQ: CYTK] plunged -0.87% to $33.11. The stock’s lowest price that day was $32.63, but it reached a high of $33.26 in the same session. During the last five days, there has been a surge of approximately 1.75%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -38.14%. Shares of the company reached a 52-week high of $52.80 on 01/27/25 and a 52-week low of $29.31 on 05/15/25.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 32.74, which, if violated, would cause prices to drop to 32.37. In the upper region, resistance lies at 33.37. The next price resistance is at 33.63. RSI (Relative Strength Index) is 49.93 on the 14-day chart, showing neutral technical sentiment.
Is Cytokinetics Inc subject to short interest?
Stocks of Cytokinetics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 18384.0 shares to 14.5 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 14.48 million shares. A jump of 0.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.07 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.07.
Which companies own the most shares of Cytokinetics Inc (CYTK)?
In terms of Cytokinetics Inc share price expectations, FactSet research, analysts set an average price target of 61 in the next 12 months, up nearly 82.63% from the previous closing price of $33.4. Analysts anticipate Cytokinetics Inc stock to reach 67 by 2025, with the lowest price target being 55. In spite of this, 12 analysts ranked Cytokinetics Inc stock as Buy at the end of 2025. On August 13, 2024, Goldman assigned a price target of “a Neutral” to the stock and downgraded coverage with a $60.
